Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Delivering AI-powered pathology to drive insight in cancer diagnosis

Proscia
By Author Proscia | March 22, 2022

Users of Concentriq Dx can now leverage the full suite of Visiopharm’s AI applications directly in the routine workflow, helping pathologists quantify the expression of biomarkers aiming to accelerate treatment decisions for patient care.

Our website uses cookies. By using this site, you agree to its use of cookies.